AVANEX 2-73

The European Rett Syndrome Conference gets underway Friday in Finland. Among the presenters: a New York-based micro-cap biotech that has an investigational asset to treat Rett syndrome in its pipeline.   Anavex Life Sciences Corp (NASDAQ: AVXL), founded in 2006, is a biotech that focuses...

Anavex Life Sciences Corp (NASDAQ: AVXL) announced earlier Wednesday that it has signed a material transfer agreement with Biogen Inc (NASDAQ: BIIB), giving the latter the right to test its lead candidate AVANEX 2-73 in an oligodendrocyte precursor cell differentiation assay, or OPC. OPC is used...